Portage Biotech Announces Late Breaking Data Presentation of PORT-5 (STI-001) at 2022 AACR Annual Meeting

Portage Biotech, Inc.

Preclinical data will be presented in a late-breaking abstract session

WESTPORT, Conn., March 09, 2022 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve lives patients and increase survival by preventing and overcoming resistance to cancer treatment, and Stimunity, an early-stage biotechnology company focused on developing a unique STING agonist based on virus-like particles, announced today data from a collaboration on a STING-activating therapy, PORT-5 (STI-001) will be presented at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) taking place April 8-13, 2022 in New Orleans, Louisiana.

“The interferon gene stimulator (STING) pathway is a well-recognized immune stimulation pathway and has long been an area of ​​interest in cancer therapy, but therapies that activate STING have historically been limited in trials. clinics due to delivery issues,” said Dr. Ian Walters, CEO of Portage. “We are grateful to the Scientific Committee for finding the research on our systemically administered STING-based therapy, PORT-5, to be very important and timely for inclusion in the AACR Late Breaking Session and we are look forward to sharing more updates in the coming month.

Presentation details

Title of abstract: Cell selectivity of STING stimulation determines priming of anti-tumor T cell responses
Abstract number: 7829
Presenter: Bakhos Jneid, Curie Institute
Session title: Last Minute Research: Experimental and Molecular Therapeutics 2
Session Date/Time: April 13, 2022, 9:00 a.m. to 12:30 p.m. CST
Location: Section 16 Poster

About Portage Biotech Inc.
Portage is a clinical-stage immuno-oncology company providing cutting-edge therapies that target known resistance pathways at checkpoints to improve long-term treatment response and quality of life for patients with evasive cancers. The Company’s access to next-generation technologies, combined with an in-depth understanding of biological mechanisms, helps identify the most promising clinical therapies and product development strategies that accelerate these drugs into the translational pipeline. Portage’s portfolio consists of five diverse platforms, leveraging intratumoral delivery, nanoparticles, liposomes, aptamers and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

About PORT-5 (STI-001)
PORT-5 offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist into a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to specific cells. The therapy can be delivered systemically while stimulating targeted and specific immune activation. One or more targeted agents can be packaged into the VLP to enhance its potency. PORT-5 is currently in preclinical studies and is being advanced in collaboration with Stimunity and Institut Curie.

Forward-looking statements

This press release contains statements about the Company’s information that are forward-looking in nature and, therefore, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them, as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company undertakes no obligation to publicly update or revise any forward-looking statements or information, except as required by law.

FOR MORE INFORMATION PLEASE CONTACT:

Investor Relations
Chuck Padala
[email protected]

Media Relations
Gwen Schanker
[email protected]

Comments are closed.